Zhu Wei
Shanghai Xi Rong Information Science and Technology Company Limited, National Science and Technology Park, School of Life Sciences and Technology, Tongji University, Shanghai 200092, China.
World J Gastrointest Pharmacol Ther. 2025 Sep 5;16(3):108190. doi: 10.4292/wjgpt.v16.i3.108190.
Hepatitis B virus (HBV) is one of the major micro-pathogens in the progression of chronic liver infections worldwide. Despite a vaccine and anti-virus drugs used in the management of HBV infection, the prognosis and outcomes of this chronic infection remain complex and the infection can easily recur. Several parameters such as host age, viral mutations and genotypes, regional distributions, . have an effect on the outcome of hepatitis B infection following preventive measures and therapy around viral life cycle in the clinic. In addition, the economic status in different regions and groups of patients also affect disease progression. A cost-effectiveness analysis is considered to play a critical role in the management of chronic HBV infection. This mini-review investigates the above-mentioned aspects and provides a perspective viewpoint for the management of HBV infection in the future.
乙型肝炎病毒（HBV）是全球慢性肝脏感染进展中的主要微观病原体之一。尽管有用于管理HBV感染的疫苗和抗病毒药物，但这种慢性感染的预后和结果仍然复杂，且感染很容易复发。宿主年龄、病毒突变和基因型、区域分布等几个参数……在临床上围绕病毒生命周期采取预防措施和治疗后，对乙型肝炎感染的结果有影响。此外，不同地区和患者群体的经济状况也会影响疾病进展。成本效益分析被认为在慢性HBV感染的管理中起着关键作用。本综述探讨了上述方面，并为未来HBV感染的管理提供了一个前瞻性观点。
